Rebecca Araujo

DocwireNews

A study presented at the <a href="https://www.hoparx.org/hopa-learn/conferences-events/" target="_blank" rel="noopener">Hematology/Oncology Pharmacy Association Annual Conference 2024</a> utilized data from a real-world setting to identify predictive factors for dose reduction among patients with advanced or metastatic <a href="https://docwirenews.com/post/tapering-steroids-prior-to-paclitaxel-for-breast-cancer-does-not-increase-infusion-reactions">breast cancer</a> receiving palbociclib.
In total, 149 patients treated at a single center in Montreal, Quebec, Canada, were included. Patients had locally advanced unresectable or metastatic HR+/HER2− breast cancer and were treated with palbociclib in combination with letrozole (59.7%) or fulvestrant (40.3%). The primary end point was the identification of baseline characteristics that were predictive for the need for palbociclib dose reduction during treatment. Other end points included treatment patterns, clinical outcomes (including progression-free survival [PFS]), and the frequency and type of interventions carried out by oncology pharmacists for these patients.
Overall, 37.6% of patients required a dose reduction. The number of dose reductions ranged from 1 to 3. The recommended starting dose was 125 mg/day, and the average dose after first reduction was 100 mg/day. The average time to first reduction was 99.5 days.
The most common reason for the initial dose reduction was advanced age (42.8%), followed by comorbidities (28.6%), prevention of toxicities (21.4%), drug interaction (14.3%), Eastern Cooperative Oncology Group performance status ≥2 (14.3%), and hepatic insufficiency (7.1%). When considering all dose reductions during treatment, the most common reason for reductions was side effects (93.4%)—in 84.7% of cases, the side effect responsible for the dose reduction was neutropenia.
Median PFS was 20.4 months (95% CI, 9.6-31.3) in the dose reduction group and 14.1 months (95% CI, 9.1-19.1) in the no reduction group. The average number of pharmacist interventions per patient was 14.4 (range, 3.0-73.0). The most common types of pharmacist intervention were an oncology nurse call (17.5%), community pharmacy calls (13.7%), and an initial meeting with education (12.5%).
Assessment of predictive factors of dose reduction showed that absolute neutrophil count (ANC) &lt;3.5 × 109/L at the start of treatment and age ≥70 years were both significantly associated with reduction. The odds ratio (OR) for dose reduction with an ANC &lt;3.5 × 109/L was 3.120 (95% CI, 1.516-6.422; P=.002). The OR for age ≥70 years was 2.1 (95% CI, 1.063-4.148; P=.033).
In summary, the authors wrote, “These real-world data suggest that patients aged ≥70 years and those whose ANC before initiating treatment is &lt;3.5 × 109/L may benefit from an upfront dose reduction as they are at higher risk for a dose reduction of palbociclib during treatment.”
<h4>Reference</h4>
Savignan S, Boyer M, Messier C, Monfette ML, Letarte N. Predictive factors of dose reduction among patients treated with palbociclib for advanced or metastatic breast cancer in a real-world setting. Poster. Presented at the Hematology/Oncology Pharmacy Association Annual Conference 2024; April 3-6, 2024; Tampa, Florida.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Older Age Associated With Palbociclib Dose Reduction in Patients With Advanced Breast Cancer

HOPA Annual Conference 2024

Patients ≥70 years of age were more likely to have a reduction in their palbociclib dosage during treatment for advanced or metastatic breast cancer. 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe